Works matching IS 11707690 AND DT 2003 AND VI 21 AND IP 5
Results: 14
A Model to Assess the Cost Effectiveness of Statins in Achieving the UK National Service Framework Target Cholesterol Levels.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 1, doi. 10.2165/00019053-200321001-00001
- By:
- Publication type:
- Article
An Economic Analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 13, doi. 10.2165/00019053-200321001-00002
- By:
- Publication type:
- Article
A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 25, doi. 10.2165/00019053-200321001-00003
- By:
- Publication type:
- Article
Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 33, doi. 10.2165/00019053-200321001-00004
- By:
- Publication type:
- Article
The Economic Burden of Stroke in the United Kingdom.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 43, doi. 10.2165/00019053-200321001-00005
- By:
- Publication type:
- Article
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 357, doi. 10.2165/00019053-200321050-00007
- By:
- Publication type:
- Article
Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Peginterferon α-2a (40kD) [Pegasys[sup ®]] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon[sup ®]-A]: In Patients with Chronic Hepatitis C.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 341, doi. 10.2165/00019053-200321050-00005
- By:
- Publication type:
- Article
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
- Published in:
- 2003
- By:
- Publication type:
- journal article
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Cost Effectiveness of Alendronate (Fosamax[sup ®]) for the Treatment of Osteoporosis and Prevention of Fractures.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 305, doi. 10.2165/00019053-200321050-00002
- By:
- Publication type:
- Article
A simulation model for estimating direct costs of type 1 diabetes prevention.
- Published in:
- 2003
- By:
- Publication type:
- journal article